Avernatx
62 employees on LinkedIn · 4 known investors
Averna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.
Founders & leadership
TM
Thomas M. BarnesCEO & Board Member
Investors · 4
Competitors · 7
by search overlap
Orna46 shared keywordsOrna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
ロゴマーク：AIRNA41 shared keywordsAIRNA develops RNA editing therapeutics aimed at providing functional cures for patients with rare diseases and common conditions. The company works in the genetic medicines and biotech space.
Inspirna33 shared keywordsInspirna is a clinical-stage biopharmaceutical company developing first-in-class cancer therapeutics, including oral small molecules and biologics that target newly discovered drivers of metastasis in common cancers such as colorectal, non-small cell lung, and endometrial cancer. It uses its proprietary RNA-DRIVEr platform and microRNA mapping to identify cancer drivers for patients with high unmet medical needs.
Bioworld33 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Innorna31 shared keywordsInnorna develops mRNA-based therapeutics built on a proprietary platform featuring a lipid library of over 100,000 ionizable lipid structures and targeted LNP delivery systems. The company's pipeline spans vaccines, protein replacement therapies for chronic metabolic diseases, and in vivo immunotherapies for autoimmune conditions, with four candidates in clinical trials.
Sionnatx31 shared keywordsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
Transcode Therapeutics31 shared keywordsTransCode Therapeutics is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b to treat patients with metastatic cancer and is in Phase 2a clinical trials.
Companies competing with Avernatx for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Avernatx do?
- Averna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.
- Who are Avernatx's investors?
- Avernatx's investors include Deep Insight, Delos Capital, Novartis Venture Fund, OrbiMed.